• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

byConstance Wu
August 27, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo.

2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Migraine is a common and debilitating headache condition. Treatment with triptans for acute episodes are often either not effective or can be contraindicated in certain patients. Calcitonin gene–related peptide (CGRP) has been associated with migraine pathology, and prior studies have shown inhibition of CGRP can effectively treat migraine. This phase 3 randomized controlled trial compared the CGRP small molecule inhibitor rimegepant to placebo for acute migraine treatment. The primary outcome of pain 2 hours after treatment administration showed more patients were pain free and free of their most bothersome symptoms when treated with rimegepant compared to placebo. Nausea and urinary tract infections were the most common adverse events and reported at similar rates in the treatment and placebo groups.

This large randomized study provides clinically meaningful, patient-centric data to suggest rimegepant as an efficacious treatment of acute migraine. The study is significantly limited by its lack of comparison to a triptan, or other active drug treatment.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: headachemigrainerimegepanttriptan
Previous Post

2 Minute Medicine Rewind August 26, 2019

Next Post

FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

RelatedReports

Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

November 14, 2022
Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

July 4, 2022
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Emergency

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

October 11, 2021
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Chronic Disease

Atogepant effective in reducing migraine and headache days

October 4, 2021
Next Post
FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

#VisualAbstract: Trial of Galcanezumab in Prevention of Episodic Cluster Headache

#VisualAbstract: Trial of Galcanezumab in Prevention of Episodic Cluster Headache

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options